Windows Errors? Fix Them Before They Spread
Repair common Windows errors and clear accumulated junk for a smoother, more stable PC - no reinstall needed.Free scan · no reinstallCrashes, No Sound, or Screen Glitches?
Random freezes, missing sound and display glitches usually trace back to one bad driver. Find and replace yours safely.Free scan · under a minuteShort answer: The FDA is using Elsa, an internal generative-AI assistant, to help employees with research and workflow tasks. Public sources do not show that Elsa independently approves drugs. CNN reported that current and former FDA staff said the system sometimes invented studies or distorted research, but there is no published independent error rate or measurement showing how much Elsa has shortened drug-approval timelines.
Is the FDA using AI to approve drugs?
Not in the sense of handing approval authority to a machine. The FDA describes Elsa as a large-language-model assistant for employees, including scientific reviewers and investigators. It can help find, summarize, compare and organize information, but the public descriptions do not establish that it makes final approval decisions. Scientific judgment, regulatory conclusions and accountability remain with FDA personnel.
As an Amazon Associate I earn from qualifying purchases.
The agency announced Elsa’s launch as an internal tool in its June 2, 2025 release. That announcement says Elsa was intended to reduce repetitive work and support activities such as protocol reviews, scientific evaluations and inspection targeting.
Free tools Windows power users keep installed
One-click scans. No signup required.
What Elsa is designed to do
FDA materials describe Elsa as an assistant for reading, writing and summarizing information. Reported use cases include:
#1 Best Overall
- Summarizing adverse-event reports
- Comparing drug labels
- Generating code
- Reviewing clinical protocols
- Supporting scientific evaluations
- Helping identify inspection targets
The FDA said the initial system operated in a high-security GovCloud environment and that its models were not trained on regulated-industry submissions. Those are agency statements about the system’s design and data handling, not independent security or performance audits.
Why the FDA says Elsa can speed scientific work
In its May 8, 2025 announcement about an AI-assisted scientific-review pilot, the FDA quoted Deputy Director Jinzhong (Jin) Liu of the Office of Drug Evaluation Sciences at CDER: “This is a game-changer technology that has enabled me to perform scientific review tasks in minutes that used to take three days.”
That is an individual example from a pilot, not a controlled average. It refers to particular scientific-review tasks, not an entire drug application, a statutory approval decision or a proven reduction in the time required to approve medicines. The agency’s stated goal was to make staff more efficient; it did not publish an independently audited before-and-after approval-time result.
What FDA staff and CNN reported about mistakes
On July 23, 2025, CNN reported that current and former FDA employees said Elsa had fabricated nonexistent studies and misrepresented research. CNN’s account relied partly on anonymous sources and documents, and an employee quoted anonymously said: “It hallucinates confidently.” The report is evidence that staff raised serious concerns, not a published audit showing how often the alleged failures occurred. CNN’s reproduced report is available here.
Rank #3
In a CNN News Central transcript, FDA Commissioner Marty Makary described the expected safeguard this way: “And so it’s the responsibility of the scientific reviewer to click on that link that ELSA provides and look at the study and read the abstract.” That statement makes human checking part of the intended workflow; it does not demonstrate that every link or citation produced by Elsa is reliable.
Early reactions were not uniformly negative. RAPS reported on June 4, 2025 that some officials encountered outdated answers, while another reviewer described using Elsa to query reports and then verifying the responses. A second CNN transcript also records the agency’s explanation of the reviewer’s responsibility.
How Elsa changed from the 2025 rollout to version 4.0
The FDA’s May 6, 2026 announcement describes Elsa 4.0 and a broader platform called HALO. According to the agency, HALO consolidated more than 40 application and submission data sources, systems and portals. The release also says the system runs in a FedRAMP High Google Cloud Platform environment, does not train on user input or regulated-industry data, and uses subject-matter experts to verify inputs, analytical processes and how outputs are implemented.
Recommended Free Tools
These changes document a larger integration and a formal human-verification role. They do not, by themselves, prove that earlier hallucination concerns have been eliminated, that Elsa’s answers are accurate at a particular rate or that drug approvals became faster.
Best Value
What is established—and what is still unknown
- Established: Elsa is an internal FDA generative-AI assistant used by employees for information and workflow tasks.
- Established: The FDA has described applications in scientific review, adverse-event work, label comparison, coding, protocol review and inspections.
- Reported but not measured: A senior FDA official gave a pilot example in which certain tasks went from three days to minutes.
- Reported allegations: CNN’s sources described fabricated studies and misrepresented research, including confident hallucinations.
- Not publicly quantified: No independent Elsa error rate, hallucination frequency or average change in drug-approval time is provided in the cited material.
- Not demonstrated by the 2026 update: Elsa 4.0’s expanded integration and verification process are not an independent validation that previous problems are resolved.
Can Elsa actually speed up drug approvals?
It could shorten some tasks that occur during a review, such as searching records, preparing summaries or comparing documents. That is different from shortening the full regulatory pathway, which includes evidence assessment, questions to sponsors, benefit–risk judgments, manufacturing review and formal agency decisions.
The available public record supports a narrower conclusion: the FDA is trying to accelerate parts of its employees’ work with AI. It does not support a claim that Elsa independently approves medicines, that every use is error-prone, or that a specific percentage of approval time has been saved.
Quick Recap
Chronology
| Date | What happened | What the record shows |
|---|---|---|
| May 8, 2025 | FDA announced completion of its first AI-assisted scientific-review pilot. | The agency published Liu’s three-days-to-minutes example, without an independent average or approval-time measure. |
| June 2, 2025 | FDA announced agency-wide Elsa availability. | Elsa was presented as an internal assistant for reviewers, investigators and other employees. |
| June 4, 2025 | RAPS reported early staff reactions. | Accounts included outdated answers as well as a reviewer’s positive experience with verification. |
| July 23, 2025 | CNN reported staff allegations of fabricated studies and distorted research. | The claims came partly from anonymous employees and documents, not a published error-rate study. |
| May 6, 2026 | FDA announced Elsa 4.0 and HALO integration. | The agency described broader data integration and human subject-matter-expert checks, but supplied no independent accuracy or timeline results. |
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
Do these 3 things before closing this tab:
1Repair Windows errors before they cause bigger problems2Fix the driver behind crashes, sound loss and screen glitches3Clear out junk files and repair common Windows errors
